Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CGTX Stock Forecast 2025-2026
$0.57
Current Price
$35.17M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CGTX Price Targets
+605.5%
To High Target of $4.00
+517.3%
To Median Target of $3.50
+252.7%
To Low Target of $2.00
CGTX Price Momentum
-1.7%
1 Week Change
+90.0%
1 Month Change
-71.2%
1 Year Change
-18.6%
Year-to-Date Change
-77.6%
From 52W High of $2.54
+155.4%
From 52W Low of $0.22
📊 TOP ANALYST CALLS
Did CGTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cognition Therapeutics is one of their latest high-conviction picks.
Latest CGTX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CGTX has a bullish consensus with a median price target of $3.50 (ranging from $2.00 to $4.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $0.57, the median forecast implies a 517.3% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Daniil Gataulin at Chardan Capital, projecting a 605.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGTX Analyst Ratings
4
Buy
0
Hold
0
Sell
CGTX Price Target Range
Low
$2.00
Average
$3.50
High
$4.00
Current: $0.57
Latest CGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 26, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $3.00 |
| May 27, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $3.00 |
| May 8, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $4.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
| Mar 21, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $8.00 |
| Feb 26, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $11.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $6.00 |
| Dec 19, 2024 | B. Riley Securities | Mayank Mamtani | Buy | Upgrade | $1.50 |
| Dec 19, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $11.00 |
| Nov 27, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Nov 15, 2024 | Chardan Capital | Buy | Maintains | $0.00 | |
| Nov 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $5.00 |
| Oct 31, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $11.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $5.00 |
| Aug 6, 2024 | B. Riley Securities | Mayank Mamtani | Neutral | Downgrade | $1.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $7.00 |
| Jul 30, 2024 | Cantor Fitzgerald | Charles Duncan | Neutral | Downgrade | $0.00 |
| Jul 2, 2024 | Rodman & Renshaw | Elemer Piros | Buy | Reiterates | $14.00 |
| Jun 6, 2024 | Chardan Capital | Daniil Gataulin | Buy | Initiates | $11.00 |
| May 29, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $10.00 |
Cognition Therapeutics Inc. (CGTX) Competitors
The following stocks are similar to Cognition Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CGTX
Cognition Therapeutics
mkt cap
35.17M
Cognition Therapeutics Inc. (CGTX) Financial Data
Cognition Therapeutics Inc. has a market capitalization of $35.17M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -161.9%.
Valuation Metrics
Market Cap
$35.17M
Enterprise Value
$3.41M
P/E Ratio
0.0x
PEG Ratio
-0.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+46.7%
Current Ratio
2.1x
Debt/Equity
5.2x
ROE
-161.9%
ROA
-107.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cognition Therapeutics Inc. (CGTX) Business Model
About Cognition Therapeutics Inc.
What They Do
Develops therapeutics for neurodegenerative diseases.
Business Model
The company operates a biopharmaceutical model focused on researching and developing novel small molecule therapies specifically for Alzheimer's disease. It generates revenue by advancing its investigational drugs through clinical trials, aiming to eventually bring effective treatments to market.
Additional Information
Cognition Therapeutics utilizes a proprietary platform to identify therapies that target synaptic mechanisms in the brain. Its strong pipeline addresses significant unmet medical needs in the healthcare and life sciences sectors, positioning the company for potential growth and impact in the biotech industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
25
CEO
Ms. Lisa Ricciardi
Country
United States
IPO Year
2021
Website
www.cogrx.comCognition Therapeutics Inc. (CGTX) Latest News & Analysis
Latest News
Quick Summary
Cognition Therapeutics (NASDAQ: CGTX) held an end-of-Phase 2 meeting with the FDA on July 9, 2025, regarding its drug development for neurodegenerative disorders.
Why It Matters
Cognition Therapeutics’ FDA meeting signals potential progress in drug development, impacting timelines and investor sentiment regarding future approvals and market potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics (NASDAQ: CGTX) announced over 50% enrollment in its Phase 2 'START' Study for neurodegenerative disorders, supported by $81 million from the NIA and partnered with ACTC.
Why It Matters
Cognition Therapeutics achieving over 50% enrollment in a Phase 2 study signals progress in drug development for neurodegenerative disorders, potentially boosting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics will hold an end-of-Phase 2 meeting with the FDA on July 9, 2025, regarding treatments for mild-to-moderate Alzheimer's and has filed for IND and Breakthrough Status for dementia with Lewy bodies.
Why It Matters
The FDA meeting signals potential regulatory progress for Cognition's Alzheimer's treatment, influencing stock performance and investor sentiment in neurodegenerative drug development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced an anonymous donation to fund an expanded access program for dementia with Lewy bodies, led by Dr. James Galvin at Banner Sun Health Research Institute.
Why It Matters
Cognition Therapeutics' funding for an expanded access program signals strong support for its DLB treatment, potentially enhancing its market position and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics, Inc. (NASDAQ: CGTX) has released its tenth podcast episode focusing on the lived experiences of patients and caregivers dealing with dementia with Lewy bodies.
Why It Matters
Cognition Therapeutics' podcast highlights their focus on dementia, potentially boosting investor confidence in their research and market positioning in neurodegenerative treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cognition Therapeutics (NASDAQ: CGTX) presented preclinical data indicating that zervimesine (CT1812) may protect retinal cells from damage in dry age-related macular degeneration at the ARVO conference.
Why It Matters
Positive preclinical data for zervimesine in treating dry AMD could enhance Cognition Therapeutics' pipeline, potentially increasing its market value and attracting investor interest in neurodegenerative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CGTX Stock
What is Cognition Therapeutics Inc.'s (CGTX) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Cognition Therapeutics Inc. (CGTX) has a median price target of $3.50. The highest price target is $4.00 and the lowest is $2.00.
Is CGTX stock a good investment in 2026?
According to current analyst ratings, CGTX has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CGTX stock?
Wall Street analysts predict CGTX stock could reach $3.50 in the next 12 months. This represents a 517.3% increase from the current price of $0.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cognition Therapeutics Inc.'s business model?
The company operates a biopharmaceutical model focused on researching and developing novel small molecule therapies specifically for Alzheimer's disease. It generates revenue by advancing its investigational drugs through clinical trials, aiming to eventually bring effective treatments to market.
What is the highest forecasted price for CGTX Cognition Therapeutics Inc.?
The highest price target for CGTX is $4.00 from Daniil Gataulin at Chardan Capital, which represents a 605.5% increase from the current price of $0.57.
What is the lowest forecasted price for CGTX Cognition Therapeutics Inc.?
The lowest price target for CGTX is $2.00 from at , which represents a 252.7% increase from the current price of $0.57.
What is the overall CGTX consensus from analysts for Cognition Therapeutics Inc.?
The overall analyst consensus for CGTX is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.50.
How accurate are CGTX stock price projections?
Stock price projections, including those for Cognition Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2025 2:28 AM UTC